X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8599) 8599
Newsletter (1880) 1880
Book Review (787) 787
Publication (645) 645
Conference Proceeding (80) 80
Book Chapter (17) 17
Book / eBook (10) 10
Newspaper Article (8) 8
Magazine Article (6) 6
Dissertation (5) 5
Transcript (4) 4
Paper (2) 2
Report (2) 2
Government Document (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anthracyclines (8444) 8444
index medicus (7231) 7231
humans (5105) 5105
cancer (4328) 4328
doxorubicin (3407) 3407
pharmacology & pharmacy (3194) 3194
animals (3079) 3079
chemotherapy (2927) 2927
female (2318) 2318
doxorubicin - pharmacology (2245) 2245
oncology (2079) 2079
analysis (1949) 1949
cell line, tumor (1880) 1880
research (1872) 1872
drugs (1803) 1803
mice (1568) 1568
apoptosis (1547) 1547
male (1477) 1477
care and treatment (1374) 1374
drug delivery systems (1305) 1305
breast cancer (1295) 1295
antineoplastic agents - pharmacology (1275) 1275
antibiotics, antineoplastic - pharmacology (1193) 1193
doxorubicin - administration & dosage (1071) 1071
vehicles (1029) 1029
nanoparticles (993) 993
tumors (960) 960
rats (942) 942
breast neoplasms - drug therapy (937) 937
anthracycline (908) 908
cell survival - drug effects (882) 882
apoptosis - drug effects (875) 875
reports (874) 874
biochemistry & molecular biology (872) 872
middle aged (840) 840
drug resistance (810) 810
cardiotoxicity (807) 807
adriamycin (787) 787
doxorubicin - chemistry (771) 771
toxicity (755) 755
health aspects (750) 750
adult (727) 727
pharmacology/toxicology (718) 718
therapy (714) 714
cells (705) 705
dose-response relationship, drug (701) 701
oncology, experimental (701) 701
in-vitro (696) 696
aged (690) 690
cytotoxicity (684) 684
expression (668) 668
chemistry, multidisciplinary (653) 653
drug therapy (647) 647
toxicology (599) 599
cell proliferation - drug effects (592) 592
oxidative stress (592) 592
antibiotics, antineoplastic - administration & dosage (589) 589
doxorubicin - pharmacokinetics (588) 588
universities and colleges (585) 585
chemistry, medicinal (577) 577
proteins (574) 574
breast neoplasms - pathology (570) 570
medicine & public health (568) 568
antineoplastic combined chemotherapy protocols - therapeutic use (566) 566
neoplasms - drug therapy (565) 565
doxorubicin - therapeutic use (553) 553
p-glycoprotein (543) 543
antineoplastic agents - therapeutic use (530) 530
cell biology (529) 529
breast-cancer (527) 527
drug resistance, neoplasm (519) 519
doxorubicin - toxicity (516) 516
dna (504) 504
treatment outcome (494) 494
pharmacology (492) 492
metastasis (479) 479
drug-delivery (473) 473
in-vivo (472) 472
doxorubicin - analogs & derivatives (470) 470
antineoplastic agents - chemistry (468) 468
gene expression (457) 457
antibiotics, antineoplastic - chemistry (453) 453
cancer therapies (451) 451
leukemia (448) 448
multidrug-resistance (444) 444
drug delivery (440) 440
pharmacy (432) 432
biomedicine (429) 429
drug resistance in microorganisms (428) 428
anthracyclines - pharmacology (424) 424
cancer research (418) 418
inhibition (416) 416
tumor cells, cultured (416) 416
pharmacokinetics (412) 412
multidrug resistance (411) 411
doxorubicin - adverse effects (408) 408
mice, inbred balb c (406) 406
paclitaxel (399) 399
liposomes (398) 398
article (397) 397
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10449) 10449
Japanese (37) 37
Russian (13) 13
German (9) 9
Chinese (8) 8
French (7) 7
Italian (5) 5
Spanish (5) 5
Polish (2) 2
Slovak (2) 2
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Investigational New Drugs, ISSN 0167-6997, 6/2012, Volume 30, Issue 3, pp. 1248 - 1256
This study sought to measure the degree of synergy induced by specific small molecule inhibitors of DNA-PK [NU7026 and IC486241 (ICC)], a major component of... 
Anthracyclines | DNA-PK | Medicine & Public Health | Homologous recombination | Non-homologous end joining | Oncology | DNA-damage | Breast cancer | Pharmacology/Toxicology | DNA-repair | Drug synergism | PHOSPHORYLATION | DEPENDENT PROTEIN-KINASE | DOUBLE-STRAND BREAKS | OXALIPLATIN | DAMAGE | REPAIR | ONCOLOGY | COLORECTAL-CANCER | COMBINATION CHEMOTHERAPY | PHARMACOLOGY & PHARMACY | ATM | CYTOTOXICITY | DNA-Activated Protein Kinase - antagonists & inhibitors | Cell Survival - drug effects | HCT116 Cells | Humans | Morpholines - pharmacology | Cisplatin - pharmacology | Comet Assay | Organoplatinum Compounds - pharmacology | Drug Synergism | HT29 Cells | Topoisomerase I Inhibitors - pharmacology | Cell Cycle Checkpoints - drug effects | Colonic Neoplasms - pathology | Acridones - pharmacology | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Chromones - pharmacology | Camptothecin - pharmacology | Camptothecin - analogs & derivatives | Antimitotic agents | Complications and side effects | Colon cancer | DNA damage | Dosage and administration | Research | Antineoplastic agents | Drug therapy | Studies | Pharmacology | Deoxyribonucleic acid--DNA | Colorectal cancer | Index Medicus | Drugs | Flow cytometry | Phosphorylation | Data processing | Tumor cell lines | Synergism | Comet assay | Western blotting | Homologous recombination repair | Irinotecan | Rad51 protein | DNA-dependent protein kinase | homologous recombination | Cell cycle | oxaliplatin
Journal Article
Phytomedicine, ISSN 0944-7113, 11/2012, Volume 19, Issue 14, pp. 1288 - 1297
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2007, Volume 2, Issue 8, pp. e693 - e693
Journal Article
Biomaterials, ISSN 0142-9612, 2014, Volume 35, Issue 37, pp. 9877 - 9887
Abstract P-glycoprotein (P-gp) mediated drug efflux has been recognized as a key factor contributing to the multidrug resistance (MDR) in tumor cells. To... 
Advanced Basic Science | Dentistry | P-glycoprotein | pH-sensitive | Copolymer micelles | d-α-tocopheryl polyethylene glycol succinate | Hyaluronic acid | Multidrug resistance | D-α-tocopheryl polyethylene glycol succinate | PH-sensitive | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | SELF-ASSEMBLED NANOPARTICLES | D-alpha-tocopheryl polyethylene glycol succinate | DRUG-RESISTANCE | POLYMERIC MICELLES | CANCER | HYALURONIC-ACID | VITAMIN-E TPGS | IRON-OXIDE | IN-VITRO | INTRACELLULAR DELIVERY | TARGETED DELIVERY | Doxorubicin - therapeutic use | Histidine - pharmacology | Antibiotics, Antineoplastic - pharmacology | Drug Resistance, Multiple - drug effects | Humans | Vitamin E - analogs & derivatives | Delayed-Action Preparations - chemistry | Hyaluronic Acid - pharmacology | Polyethylene Glycols - chemistry | MCF-7 Cells | Delayed-Action Preparations - pharmacology | Micelles | Female | Vitamin E - chemistry | Doxorubicin - administration & dosage | Polyethylene Glycols - pharmacology | Hyaluronic Acid - chemistry | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Animals | Antibiotics, Antineoplastic - therapeutic use | Mice, Nude | ATP Binding Cassette Transporter, Sub-Family B - metabolism | Cell Line, Tumor | Mice, Inbred BALB C | Histidine - chemistry | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Vitamin E - pharmacology | Drug resistance in microorganisms | Anthracyclines | Histidine | Hydrogen-ion concentration | Polyols | Polyethylene glycol | Index Medicus
Journal Article
Journal Article
Oncogene, ISSN 0950-9232, 06/2001, Volume 20, Issue 26, pp. 3387 - 3398
The molecular basis for the sensitivity of tumor cells to chemopreventive natural food compounds and commonly used chemotherapeutic agents is not well... 
Chemotherapy | Colon cancer | p21 | Butyrate | p53 | P53-INDUCED APOPTOSIS | butyrate | colon cancer | NITRIC-OXIDE SYNTHASE | ANTICANCER AGENTS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DNA-DAMAGE | CYCLE ARREST | HUMAN CANCER-CELLS | chemotherapy | CELL BIOLOGY | ONCOLOGY | GROWTH ARREST | CHAIN FATTY-ACIDS | DIETARY FIBER | GENETICS & HEREDITY | Adenocarcinoma - pathology | Intracellular Membranes - physiology | Apoptosis - drug effects | Butyrates - pharmacology | Humans | Neoplasm Proteins - physiology | Drug Resistance, Neoplasm | Stilbenes - pharmacology | Toluene - analogs & derivatives | Tumor Suppressor Protein p53 - physiology | Genes, p53 | Amino Acid Chloromethyl Ketones - pharmacology | Recombination, Genetic | Antineoplastic Agents - pharmacology | Cyclins - physiology | Gene Expression Regulation, Neoplastic - drug effects | Toluene - pharmacology | Anticarcinogenic Agents - pharmacology | Membrane Potentials - drug effects | Cyclin-Dependent Kinase Inhibitor p21 | Demecolcine - pharmacology | Tumor Cells, Cultured - drug effects | Etoposide - pharmacology | Cisplatin - pharmacology | Mitochondria - drug effects | Colonic Neoplasms - pathology | Cysteine Proteinase Inhibitors - pharmacology | Alleles | Fluorouracil - pharmacology | Intracellular Membranes - drug effects | Thiazoles - pharmacology | Apoptosis - physiology | Doxorubicin - pharmacology | Benzothiazoles | Anthracyclines | Carcinoma | Membrane potentials | Etoposide | Mitochondrial DNA | Fatty acids | Prevention | Resveratrol | Physiological aspects | Tumor proteins | Health aspects | Cancer | Apoptosis | Index Medicus
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 2005, Volume 70, Issue 11, pp. 1568 - 1578
Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death worldwide. In light of the very poor 5 year survival new therapeutic... 
Insulin-like growth factor receptor | Tarceva | EGF | Chemoprevention | IGF | Doxorubicin | Epidermal growth factor receptor | Statins | Cisplatin | Erbitux | Erbitux (TM) | UNITED-STATES | COA REDUCTASE INHIBITOR | APOPTOSIS | FACTOR RECEPTOR FAMILY | epidermal growth factor receptor | ANTIBODY | insulin-like growth factor receptor | FACTOR-ALPHA | P53 | chemoprevention | statins | Tarceva (TM) | PHARMACOLOGY & PHARMACY | doxorubicin | cisplatin | HEPATOMA-CELL LINES | CARCINOMA | EXPRESSION | Erlotinib Hydrochloride | Fatty Acids, Monounsaturated - pharmacology | Apoptosis - drug effects | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Indoles - pharmacology | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cetuximab | Drug Evaluation, Preclinical | Drug Therapy, Combination | Antibodies, Monoclonal - pharmacology | Liver Neoplasms - drug therapy | Tyrphostins - pharmacology | Cisplatin - pharmacology | Cell Division - drug effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Cycle - drug effects | Quinazolines - pharmacology | Doxorubicin - pharmacology | Tyrosine | Anthracyclines | Care and treatment | Growth | Immunoglobulin G | Peptide hormones | Prevention | Liver cancer | Epidermal growth factor | Monoclonal antibodies | Tumor proteins | Cancer | Index Medicus
Journal Article
Journal Article
Nature Communications, ISSN 2041-1723, 2013, Volume 4, Issue 1, pp. 1908 - 1908
Journal Article
Biomaterials, ISSN 0142-9612, 2012, Volume 34, Issue 9, pp. 2277 - 2288
Abstract Interstitial fluid pressure (IFP) in tumor is much higher than that in normal tissue and it constitutes a great obstacle for the delivery of... 
Advanced Basic Science | Dentistry | Tumor interstitial fluid pressure | Intratumoral delivery | Imatinib | Combination therapy | Doxorubicin | Sterically stabilized liposome | VASCULAR NORMALIZATION | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | PHASE-II | CANCER | ANTICANCER THERAPEUTICS | MESYLATE | PDGFR-BETA | MELANOMA | INHIBITION | GENE-EXPRESSION | DRUG-COMBINATION | Immunohistochemistry | NIH 3T3 Cells | Apoptosis - drug effects | Melanoma, Experimental - drug therapy | Drug Delivery Systems | Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors | Doxorubicin - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Drug Therapy, Combination | Fibroblasts - metabolism | Polyethylene Glycols - pharmacology | Receptor, Platelet-Derived Growth Factor beta - metabolism | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Extracellular Fluid - drug effects | Animals | Fibroblasts - drug effects | Cell Proliferation - drug effects | Mice | Liposomes - pharmacology | Doxorubicin - pharmacology | Anthracyclines | Chemotherapy | Biological products | Platelet-derived growth factor | Biomimetics | Oncology, Experimental | Melanoma | Physiological aspects | Research | Cancer | Index Medicus
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 08/2014, Volume 278, Issue 3, pp. 238 - 248
Pharmacokinetic drug resistance is a serious obstacle that emerges during cancer chemotherapy. In this study, we investigated the possible role of aldo-keto... 
Anthracyclines | Aldo-keto reductase 1C3 | Drug resistance | Metabolism | Enzyme induction | DOXORUBICIN | TUMOR-CELLS | INDUCTION | STEROID-HORMONE | DAUNORUBICIN | ENDOMETRIAL CANCER | BREAST-CANCER | 5 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3 | PROSTATE-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MCF-7 CELLS | Antibiotics, Antineoplastic - pharmacology | Humans | Daunorubicin - agonists | Daunorubicin - pharmacology | Idarubicin - pharmacology | Neoplasm Proteins - antagonists & inhibitors | Neoplasm Proteins - metabolism | Anthracyclines - agonists | Hydroxyprostaglandin Dehydrogenases - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Anthracyclines - pharmacology | Biotransformation | Anthracyclines - metabolism | Enzyme Induction - drug effects | 3-Hydroxysteroid Dehydrogenases - metabolism | Doxorubicin - metabolism | Daunorubicin - metabolism | Neoplasm Proteins - genetics | Antibiotics, Antineoplastic - agonists | Carcinoma - drug therapy | Idarubicin - metabolism | Recombinant Proteins - metabolism | Cell Survival - drug effects | Oxidation-Reduction | Flavanones - pharmacology | Enzyme Inhibitors - pharmacology | Recombinant Proteins - chemistry | Hydroxyprostaglandin Dehydrogenases - genetics | Drug Synergism | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Cell Line, Tumor | Kinetics | 3-Hydroxysteroid Dehydrogenases - genetics | Antibiotics, Antineoplastic - metabolism | Idarubicin - agonists | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Physiological aspects | Chemotherapy | Cancer cells | Cancer | Index Medicus |